IDYA Stock Forecast & Price Target

IDEAYA Biosciences is viewed favorably because DLL3 appears to be a highly validated target in aggressive neuroendocrine cancers, with expression reported in up to 90% of SCLC and 80% of extrapulmonary NECs and a U.S. TAM exceeding $4.5Bn in treatment-naïve ES-SCLC and epNEC. The company’s IDE849 program has shown encouraging efficacy, including 73% ORR, 48% confirmed ORR, and 6.7 months median PFS across all patients, with 83% ORR in brain metastases and manageable safety comparable to established TOP1i ADCs. Positive FDA discussions and a planned randomized Phase 3 monotherapy study by YE26 strengthen the registrational path, while a broader pipeline spanning darovasertib, IDE397, and other targeted programs supports long-term optionality.

IDEAYA Biosciences is highly exposed to fundamental clinical and regulatory uncertainty because its value depends on darovasertib, IDE397, and IDE849 proving both efficacious and safe in trials and then winning FDA and foreign approvals. The company also faces intense competition from larger, better-resourced biotechnology and pharmaceutical peers, raising the risk that its programs encounter superior therapies, slower adoption, or lower-than-expected sales. On the financial side, the expectation of additional equity financing to fund development points to meaningful dilution risk for existing shareholders, while any R&D, regulatory, or commercial setback could pressure the stock further.